Market Cap 358.49M
Revenue (ttm) 0.00
Net Income (ttm) -22.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,362,600
Avg Vol 1,899,274
Day's Range N/A - N/A
Shares Out 81.66M
Stochastic %K 3%
Beta 1.45
Analysts Strong Sell
Price Target $8.17

Company Profile

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to resear...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 745 6330
Address:
2440 Research Boulevard, Suite 400, Rockville, United States
Stocksman45
Stocksman45 Oct. 24 at 8:14 PM
$IMAB https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 9:44 AM
BTIG updates rating for I-MAB ( $IMAB ) to Buy, target set at 9.
0 · Reply
Stocksman45
Stocksman45 Oct. 23 at 5:11 PM
$IMAB Phase 3 drug 2026: VIS-101, to be acquired by Visara, a newly formed I-Mab subsidiary, under the new business model, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME, and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.
0 · Reply
Caresto
Caresto Oct. 23 at 2:57 PM
$IMAB NASDAQ +0.55%, XBI +0.23%, IMAB -4.56%. Others climb, IMAB sinks. That’s not random — that’s traders walking away. Rebrands don’t fix fundamentals. They just tell you the story stopped working.
0 · Reply
Whales22
Whales22 Oct. 23 at 5:54 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $SKLZ $BTSG $IMAB $NRG Watchlist \
0 · Reply
vulture2
vulture2 Oct. 23 at 2:20 AM
$FDMT Notice how caronte keeps pumping the same losing tickers — $IMAB, $OPEN, $TNYA — all downtrending plays. Classic bot behavior: hype without logic, same script everywhere. Block the noise and focus on real analysts like ReturnOfEsquire and Caresto.
0 · Reply
caronte
caronte Oct. 23 at 2:13 AM
$FDMT stay long you can find the activity of such bots also on $IMAB , $OPEN , $TNYA . always bearish, exaggerating and dramatizing any negative performance and always changing username. mute them and their bs.
0 · Reply
vulture2
vulture2 Oct. 22 at 7:12 PM
$IMAB If -7% on a down day hurts, wait till the real correction starts. No catalyst, no floor — just faith and hope. Good luck holding that. 📉
0 · Reply
vulture2
vulture2 Oct. 18 at 6:07 PM
$IMAB The SEC Rule 201 (aka "Up-Tick Rule") has been triggered and the related exchanges have implemented a short sale restriction in accordance with their policies. Short selling is still permitted when the SEC Rule 201 criteria are met. Short sale restriction is in effect from Oct 17, 06:39 to Oct 20, 17:00 PST - — translation: selling pressure is real and momentum is bearish. SSR is damage control, not strength. SSR only slows shorts. The dead cat bounce already happened — more downside likely. The trend remains bearish with no clear catalysts and heavy uncertainty around the Hong Kong IPO + rebrand plan.
0 · Reply
vulture2
vulture2 Oct. 17 at 6:39 PM
$IMAB Rebrand + upcoming IPO screams financing need, not growth. Analyst upgrades often show up right before dilution to attract new buyers. Read between the lines, not the headlines.
1 · Reply
Latest News on IMAB
I-Mab to Participate in September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 2 months ago

I-Mab to Participate in September Investor Conferences


Everest Medicines Expands Strategic Investment in I-MAB

Aug 1, 2025, 8:56 AM EDT - 3 months ago

Everest Medicines Expands Strategic Investment in I-MAB


I-Mab to Present at Jefferies Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 5 months ago

I-Mab to Present at Jefferies Global Healthcare Conference


I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

Mar 7, 2025, 7:00 AM EST - 8 months ago

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress


I-Mab Reports Third Quarter 2024 Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

I-Mab Reports Third Quarter 2024 Results


I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Nov 6, 2024, 7:00 AM EST - 1 year ago

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer


I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024, 4:01 PM EDT - 1 year ago

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024


I-MAB (IMAB) Q2 2024 Earnings Call Transcript

Aug 28, 2024, 11:50 AM EDT - 1 year ago

I-MAB (IMAB) Q2 2024 Earnings Call Transcript


I-Mab to Release 1H 2024 Financial Results on August 28, 2024

Aug 14, 2024, 7:00 AM EDT - 1 year ago

I-Mab to Release 1H 2024 Financial Results on August 28, 2024


I-Mab Announces Leadership Transitions

Jul 15, 2024, 7:30 AM EDT - 1 year ago

I-Mab Announces Leadership Transitions


I-MAB Filed 2023 Annual Report on Form 20-F

Apr 30, 2024, 7:00 AM EDT - 1 year ago

I-MAB Filed 2023 Annual Report on Form 20-F


I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 18, 2024, 3:28 AM EST - 1 year ago

I-Mab: Trading Below Net Cash With Multiple Upside Options


I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023


Stocksman45
Stocksman45 Oct. 24 at 8:14 PM
$IMAB https://www.tipranks.com/news/company-announcements/i-mab-reports-positive-phase-i-results-for-givastomig-in-gastroesophageal-cancer
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 9:44 AM
BTIG updates rating for I-MAB ( $IMAB ) to Buy, target set at 9.
0 · Reply
Stocksman45
Stocksman45 Oct. 23 at 5:11 PM
$IMAB Phase 3 drug 2026: VIS-101, to be acquired by Visara, a newly formed I-Mab subsidiary, under the new business model, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME, and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.
0 · Reply
Caresto
Caresto Oct. 23 at 2:57 PM
$IMAB NASDAQ +0.55%, XBI +0.23%, IMAB -4.56%. Others climb, IMAB sinks. That’s not random — that’s traders walking away. Rebrands don’t fix fundamentals. They just tell you the story stopped working.
0 · Reply
Whales22
Whales22 Oct. 23 at 5:54 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $SKLZ $BTSG $IMAB $NRG Watchlist \
0 · Reply
vulture2
vulture2 Oct. 23 at 2:20 AM
$FDMT Notice how caronte keeps pumping the same losing tickers — $IMAB, $OPEN, $TNYA — all downtrending plays. Classic bot behavior: hype without logic, same script everywhere. Block the noise and focus on real analysts like ReturnOfEsquire and Caresto.
0 · Reply
caronte
caronte Oct. 23 at 2:13 AM
$FDMT stay long you can find the activity of such bots also on $IMAB , $OPEN , $TNYA . always bearish, exaggerating and dramatizing any negative performance and always changing username. mute them and their bs.
0 · Reply
vulture2
vulture2 Oct. 22 at 7:12 PM
$IMAB If -7% on a down day hurts, wait till the real correction starts. No catalyst, no floor — just faith and hope. Good luck holding that. 📉
0 · Reply
vulture2
vulture2 Oct. 18 at 6:07 PM
$IMAB The SEC Rule 201 (aka "Up-Tick Rule") has been triggered and the related exchanges have implemented a short sale restriction in accordance with their policies. Short selling is still permitted when the SEC Rule 201 criteria are met. Short sale restriction is in effect from Oct 17, 06:39 to Oct 20, 17:00 PST - — translation: selling pressure is real and momentum is bearish. SSR is damage control, not strength. SSR only slows shorts. The dead cat bounce already happened — more downside likely. The trend remains bearish with no clear catalysts and heavy uncertainty around the Hong Kong IPO + rebrand plan.
0 · Reply
vulture2
vulture2 Oct. 17 at 6:39 PM
$IMAB Rebrand + upcoming IPO screams financing need, not growth. Analyst upgrades often show up right before dilution to attract new buyers. Read between the lines, not the headlines.
1 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 6:19 PM
BTIG has updated their rating for I-MAB ( $IMAB ) to Buy with a price target of 9.
0 · Reply
Stocksman45
Stocksman45 Oct. 17 at 3:50 PM
$IMAB Jefferies ups IMAB target to $10 today.
0 · Reply
Stocksman45
Stocksman45 Oct. 17 at 3:49 PM
$IMAB I-Mab plans to rebrand as NovaBridge Biosciences and pursue a dual listing with a Hong Kong IPO while maintaining its NASDAQ presence, according to Jefferies.
0 · Reply
Stocksman45
Stocksman45 Oct. 17 at 3:13 PM
$IMAB Upgrade and modern info…. https://www.investing.com/news/analyst-ratings/imab-stock-price-target-raised-to-10-by-jefferies-on-rebranding-new-asset-93CH-4294078
0 · Reply
prismmarketview
prismmarketview Oct. 17 at 2:47 PM
$IMAB I-Mab Unveils Strategic Global Shift with Hong Kong IPO Plans and Rebrand to NovaBridge Biosciences https://prismmarketview.com/i-mab-unveils-strategic-global-shift-with-hong-kong-ipo-plans-and-rebrand-to-novabridge-biosciences/
0 · Reply
vulture2
vulture2 Oct. 17 at 1:58 PM
$IMAB Pursuing HK IPO tells you everything — they need money. Listing overseas + name change is not strategy, it’s survival mode. Show revenue or real data, not rebranding.
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 17 at 1:42 PM
$ELWS -14%[-33%] $EVAX -14%[-19%] $SNSE -13%[-13%] $GWH -8%[6%] $IMAB -8%[-14%] most notable movement within the first minutes of trading.
0 · Reply
Szilis793
Szilis793 Oct. 17 at 12:30 PM
$IMAB new price target from $5=> $10
0 · Reply
ForeverBulls
ForeverBulls Oct. 17 at 10:15 AM
$IMAB IMAB - I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
0 · Reply
larsson13
larsson13 Oct. 16 at 9:58 PM
$IMAB big pump tomottow
1 · Reply
vulture2
vulture2 Oct. 16 at 9:09 PM
$IMAB Rebrand + Hong Kong IPO = classic distraction move. Companies with strong pipelines don’t need identity makeovers to stay alive. Smells like cash grab + dilution ahead.
0 · Reply
vulture2
vulture2 Oct. 16 at 7:37 PM
$IMAB — Let’s be real here. They’ve bet the entire company on one asset: givastomig (CLDN18.2 × 4-1BB bispecific). No revenue, no approvals, no backup pipeline anymore. Uliledlimab? Paused. Other programs? Gone. This is a one-drug biotech with early-stage data and a long runway before we even see if it works. Next "catalyst"? Maybe dose escalation data in late 2025 — and that’s assuming no enrollment delays or safety red flags. Dose expansion readout? Not till 2026. That’s a long wait in biotech time. Cash? ~$168M left. They say it's enough into 2027, but what happens when trials drag or data underwhelms — dilution risk is real. CLDN18.2 space is crowded — Astellas, Legend, even Amgen are circling this target. Differentiation or bust. They did buy out Bridge Health to clean up IP… but no partners, no big pharma buy-in, and their China divestment is like survival mode than strategic clarity. Unless this one shot hits — and hits hard — the runway ends with a wall. Risk > reward here.
1 · Reply